 NESS ZIONA, Israel, July 26, 2021 GLOBE NEWSWIRE -- BiomX Inc. NYSE American: PHGE BiomX or the Company, a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announced today it has entered into a definitive agreement with institutional investors, all of the Companys directors and certain executive officers for the purchase and sale of an aggregate of 3,750,000 shares of the Companys common stock and warrants to purchase an aggregate of 2,812,501 shares of the Companys common stock in a registered direct offering, for expected gross proceeds of 15 million before deducting placement agent fees and offering expenses and assuming that none of the warrants are exercised. 